Full name
A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belimumab Administered Subcutaneously in Adults With Interstitial Lung Disease (ILD) Associated With Connective Tissue Disease (CTD)
NCT Number
NCT06572384
Geography
US
Non-US
Locations
Argentina, Australia, Belgium, Brazil, Canada, China, France, Germany, Greece, Italy, Japan, Republic of Korea, Mexico, Netherlands, Panama, Spain, United States
Primary Endpoints
Absolute Change from Baseline in Forced Vital Capacity (FVC) milliliter (mL) at Week 52
External Link
https://clinicaltrials.gov/study/NCT06572384
Order
1
Disease
Version
Phase
3